Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

Recruiting

Phase 1

Phase 2

Triple Immune RegimenEvaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Code:

NCT06071767

Conditions

HIV-1-infection

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ChAdOx1.tHIVconsv1

ChAdOx1.HIVconsv62

MVA.tHIVconsv3

MVA.tHIVconsv4

Vesatolimod (VES)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-17. This information was provided to ClinicalTrials.gov by National Institute of Allergy and Infectious Diseases (NIAID) on 2025-02-05.